share_log

MannKind (NASDAQ:MNKD) Shares Gap Down After Earnings Miss

MannKind (NASDAQ:MNKD) Shares Gap Down After Earnings Miss

曼肯德(纳斯达克代码：MNKD)盈利低于预期后股价差距缩小
Defense World ·  2022/08/11 01:52

MannKind Co. (NASDAQ:MNKD – Get Rating)'s share price gapped down before the market opened on Wednesday following a dissappointing earnings announcement. The stock had previously closed at $4.09, but opened at $3.95. MannKind shares last traded at $4.34, with a volume of 48,786 shares traded.

周三，在令人失望的财报公布后，曼肯德公司(纳斯达克代码：MNKD-GET Rating)的股价在开盘前大幅下跌。该股此前收于4.09美元，开盘报3.95美元。曼肯德股票最新报4.34美元，总成交量为48,786股。

The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The business had revenue of $18.90 million during the quarter, compared to analysts' expectations of $15.62 million. During the same quarter in the prior year, the firm posted ($0.05) earnings per share. The firm's quarterly revenue was down 18.9% on a year-over-year basis.

这家生物制药公司公布了本季度每股收益(0.11美元)，低于普遍预期的(0.09美元)和(0.02美元)。该业务当季营收为1,890万美元，高于分析师预期的1,562万美元。在去年同一季度，该公司公布了每股收益(0.05美元)。该公司季度营收同比下降18.9%。

Get
到达
MannKind
曼肯德
alerts:
警报：

Analyst Upgrades and Downgrades

分析师升级和下调评级

Separately, StockNews.com raised MannKind to a "sell" rating in a report on Saturday, April 30th.

另外，StockNews.com在4月30日星期六的一份报告中将MannKind的评级上调至“卖出”。

Institutional Trading of MannKind

MannKind的机构交易

Institutional investors and hedge funds have recently modified their holdings of the business. Oakworth Capital Inc. bought a new position in shares of MannKind during the 1st quarter valued at about $25,000. Northwestern Mutual Wealth Management Co. increased its position in shares of MannKind by 277.9% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 7,056 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 5,189 shares during the last quarter. Nisa Investment Advisors LLC bought a new position in shares of MannKind during the 2nd quarter valued at about $30,000. Russell Investments Group Ltd. bought a new position in shares of MannKind during the 4th quarter valued at about $39,000. Finally, International Assets Investment Management LLC bought a new position in shares of MannKind during the 1st quarter valued at about $39,000. Hedge funds and other institutional investors own 43.57% of the company's stock.
机构投资者和对冲基金最近调整了对该公司的持股。Oakworth Capital Inc.在第一季度购买了价值约25,000美元的MannKind新股头寸。西北互惠财富管理公司在第二季度增持了277.9%的曼肯德股票。西北互惠财富管理公司目前持有7,056股这家生物制药公司的股票，价值27,000美元，该公司在上个季度又购买了5,189股。NISA Investment Advisors LLC在第二季度购买了价值约3万美元的MannKind新股头寸。罗素投资集团(Russell Investments Group Ltd.)在第四季度购买了价值约3.9万美元的MannKind新股头寸。最后，国际资产投资管理公司在第一季度购买了价值约3.9万美元的MannKind股票的新头寸。对冲基金和其他机构投资者持有该公司43.57%的股份。

MannKind Stock Performance

MannKind股票表现

The stock has a market capitalization of $1.08 billion, a P/E ratio of -11.59 and a beta of 1.75. The firm has a 50-day moving average price of $3.94 and a 200 day moving average price of $3.68.

该股市值为10.8亿美元，市盈率为-11.59，贝塔系数为1.75。该公司的50日移动均线价格为3.94美元，200日移动均线价格为3.68美元。

About MannKind

关于曼肯德

(Get Rating)

(获取评级)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism.

MannKind公司是一家生物制药公司，在美国专注于内分泌和孤儿肺部疾病吸入性治疗产品的开发和商业化。它提供Afrezza，一种吸入型胰岛素，用于改善成人糖尿病患者的血糖控制。它还向成人和儿童内分泌学家以及其他治疗甲状腺功能减退症的医疗保健提供者推广胸腺功能。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on MannKind (MNKD)
  • Could Rite Aid Be an Acquisition Target, Again?
  • The How And Why of Investing in Oil Stocks
  • The How and Why of Investing in Gold Stocks
  • Workhorse Group Is Ready To Get Back On The Horse
  • A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
  • 免费获取StockNews.com关于MannKind的研究报告(MNKD)
  • Rite Aid会再次成为收购目标吗？
  • 投资石油股票的方式和原因
  • 投资黄金股票的方式和原因
  • 工作马集团准备重返赛马
  • DraftKings，Inc.的圆底开始逆转

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.

接受《MannKind Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对MannKind和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发